The potential role of antileukotriene drugs in atherosclerosis.
Developing drugs to treat atherosclerosis is a daunting task. However, recent studies of advanced human atherosclerotic lesions have yielded new information on potential mechanisms of inflammation and immune responses in late-stage human atherosclerosis. As leukotrienes (LTs) are among the most powerful inflammatory mediators known and because the 5-lipoxygenase pathway is expressed in diseased arteries, the roles of LTs in atherogenesis merit consideration. It is also of interest to consider pharmacological strategies to develop anti-LT drugs in atherogenesis.
Spanbroek
Rainer
R
Institute of Vascular Medicine, Friedrich-Schiller University of Jena Medical School, Erfurt, Germany. spanbroek@zmkh.ef.uni-jena.de
Habenicht
Andreas J R
AJ
D001094:Arachidonate 5-Lipoxygenase / Q000096:biosynthesis / Q000235:genetics; D001161:Arteriosclerosis / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D015195:Drug Design; D005544:Forecasting; D015971:Gene Expression Regulation, Enzymologic / Q000235:genetics; D006801:Humans; D020024:Leukotriene Antagonists / Q000494:pharmacology / Q000627:therapeutic use*; D016859:Lipoxygenase Inhibitors
D020024:Leukotriene Antagonists; D016859:Lipoxygenase Inhibitors; D001094:Arachidonate 5-Lipoxygenase